Literature DB >> 22789463

A meta-analysis of mortality in rheumatic diseases.

Esther Toledano1, Gloria Candelas, Zulema Rosales, Cristina Martínez Prada, Leticia León, Lydia Abásolo, Estíbaliz Loza, Loreto Carmona, Aurelio Tobías, Juan Ángel Jover.   

Abstract

INTRODUCTION: Data reporting mortality in rheumatic diseases vary widely. The objective of this systematic review and meta-analysis of published data is to provide an accurate overview of the current risk of mortality in rheumatic diseases.
METHODS: Systematic review and meta-analysis of published studies identified by a sensitive search using free text and MeSH synonyms of "mortality" and of "rheumatic diseases", in general and by specific diagnoses. Eligibility criteria were (1) study population with rheumatoid arthritis, systemic lupus erythemathosus, systemic sclerosis, vasculitis, osteoarthritis, osteoporosis, dermatomyositis, or spondyloarthritis; (2) outcome of interest mortality, reported as an standardized mortality ratio (SMR), or easily calculated from data reported; and (3) cohorts or longitudinal observational studies. Assessment of risk of bias relied on the New Castle-Ottawa scale for cohorts; only moderate to high quality studies were included. Separate meta-SMRs were calculated for specific diagnoses. Heterogeneity was studied with meta-regression.
RESULTS: A total of 32 studies were included, none in spondyloarthritis or osteoarthritis. The overall pooled SMR was 2.03 (95% confidence interval (CI) 1.79-2.29), ranging from 1.36 in psoriatic arthritis to 4.80 in vasculitis. The largest individual overall SMR came from studies on inflammatory diseases, and the specific SMR were very high for infections and pulmonary events. Heterogeneity between studies was large; however, the analysis of such heterogeneity within diseases did not provide any association with the collected variables.
CONCLUSIONS: Based on our results and on the good quality of the included studies, we can conclude that rheumatic diseases increase in general the risk of death, and especially inflammatory diseases.
Copyright © 2012 Elsevier España, S.L. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22789463     DOI: 10.1016/j.reuma.2012.05.006

Source DB:  PubMed          Journal:  Reumatol Clin        ISSN: 1699-258X


  16 in total

1.  Serious infections in patients with rheumatoid arthritis and other immune-mediated connective tissue diseases exposed to anti-TNF or rituximab: data from the Spanish registry BIOBADASER 2.0.

Authors:  Tatiana Cobo-Ibáñez; Miguel Ángel Descalzo; Estibaliz Loza-Santamaría; Loreto Carmona; Santiago Muñoz-Fernández
Journal:  Rheumatol Int       Date:  2014-01-11       Impact factor: 2.631

Review 2.  Understanding the major risk factors in the beginning and the progression of rheumatoid arthritis: current scenario and future prospects.

Authors:  Mahendra Kumar Verma; Kota Sobha
Journal:  Inflamm Res       Date:  2015-07-07       Impact factor: 4.575

3.  Direct healthcare costs and comorbidity burden among patients with psoriatic arthritis in the USA.

Authors:  Joseph F Merola; Vivian Herrera; Jacqueline B Palmer
Journal:  Clin Rheumatol       Date:  2018-07-26       Impact factor: 2.980

4.  Epigenetic activation and memory at a TGFB2 enhancer in systemic sclerosis.

Authors:  Joseph Yusup Shin; James Daniel Beckett; Rustam Bagirzadeh; Tyler J Creamer; Ami A Shah; Zsuzsanna McMahan; Julie J Paik; Margaret M Sampedro; Elena G MacFarlane; Michael A Beer; Daniel Warren; Fredrick M Wigley; Harry C Dietz
Journal:  Sci Transl Med       Date:  2019-06-19       Impact factor: 17.956

5.  Overall mortality.

Authors:  Duncan F Moore; Virginia D Steen
Journal:  J Scleroderma Relat Disord       Date:  2020-06-08

Review 6.  Stem cell transplantation for systemic sclerosis.

Authors:  Sebastian Bruera; Harish Sidanmat; Donald A Molony; Maureen D Mayes; Maria E Suarez-Almazor; Kate Krause; Maria Angeles Lopez-Olivo
Journal:  Cochrane Database Syst Rev       Date:  2022-07-29

7.  Sex differences in patients with systemic lupus erythematosus from Northwest Spain.

Authors:  Maria D Alonso; Francisco Martínez-Vázquez; Leyre Riancho-Zarrabeitia; Teresa Díaz de Terán; Jose A Miranda-Filloy; Ricardo Blanco; Carlos González-Juanatey; Javier Llorca; Miguel A González-Gay
Journal:  Rheumatol Int       Date:  2013-06-28       Impact factor: 2.631

8.  Assessment of the dimensions, construct validity, and utility for rheumatoid arthritis screening of the COPCORD instrument.

Authors:  José Moreno-Montoya; José Alvarez-Nemegyei; Belem Trejo-Valdivia; Ingris Peláez-Ballestas
Journal:  Clin Rheumatol       Date:  2013-08-24       Impact factor: 2.980

9.  Prevalence of comorbidities in systemic sclerosis versus rheumatoid arthritis: a comparative, multicenter, matched-cohort study.

Authors:  Stylianos Panopoulos; Maria Tektonidou; Alexandros A Drosos; Stamatis-Nick Liossis; Theodoros Dimitroulas; Alexandros Garyfallos; Lazaros Sakkas; Dimitrios Boumpas; Paraskevi V Voulgari; Dimitrios Daoussis; Konstantinos Thomas; Georgios Georgiopoulos; Georgios Vosvotekas; Dimitrios Vassilopoulos; Petros P Sfikakis
Journal:  Arthritis Res Ther       Date:  2018-12-04       Impact factor: 5.156

10.  A five-year model to assess the early cost-effectiveness of new diagnostic tests in the early diagnosis of rheumatoid arthritis.

Authors:  Leander R Buisman; Jolanda J Luime; Mark Oppe; Johanna M W Hazes; Maureen P M H Rutten-van Mölken
Journal:  Arthritis Res Ther       Date:  2016-06-10       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.